Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    BMS-663513
Show Display Options
RSS Create an RSS feed from your search for:
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Intervention: Drug: Urelumab (BMS-663513)
2 Completed Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Condition: B-Cell Malignancies
Interventions: Biological: Urelumab;   Biological: Rituximab
3 Active, not recruiting A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lirilumab;   Drug: Urelumab
4 Terminated A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BMS-663513
5 Terminated A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: BMS-663513
6 Active, not recruiting Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Biological: Urelumab;   Biological: Cetuximab
7 Active, not recruiting Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Condition: Malignant Tumors
Interventions: Drug: Urelumab;   Drug: Nivolumab
8 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
9 Terminated Study of BMS-663513 in Patients With Advanced Cancer
Condition: Tumors
Intervention: Drug: BMS-663513
10 Not yet recruiting Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Conditions: Urothelial Carcinoma;   Bladder Cancer
Interventions: Drug: Nivolumab in combination with Urelumab;   Drug: Nivolumab monotherapy
11 Recruiting Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Urelumab
12 Withdrawn Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: AntiCD137;   Drug: Ipilimumab
13 Completed Phase II, 2nd Line Melanoma - RAND Monotherapy
Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)
14 Recruiting Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
Conditions: Glioblastoma;   Gliosarcoma;   Recurrent Brain Neoplasm
Interventions: Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016;   Biological: Anti-PD-1;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Biological: Anti-CD137
15 Recruiting Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Conditions: Melanoma (Skin);   Skin Cancer
Interventions: Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2

Indicates status has not been verified in more than two years